Michelle Mcmurry-Heath Sells 12,000 Shares of Bioventus (NASDAQ:BVS) Stock

Bioventus Inc. (NASDAQ:BVS) Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This represents a 21.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bioventus Stock Up 0.2%

Shares of NASDAQ:BVS opened at $8.62 on Friday. The stock has a market capitalization of $716.75 million, a price-to-earnings ratio of 26.12 and a beta of 0.78. Bioventus Inc. has a 1-year low of $5.81 and a 1-year high of $10.13. The company’s fifty day moving average is $8.25 and its two-hundred day moving average is $7.54. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $157.90 million for the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its holdings in Bioventus by 17,156.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares during the last quarter. Covestor Ltd grew its stake in shares of Bioventus by 28.0% in the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after purchasing an additional 2,176 shares during the last quarter. PharVision Advisers LLC acquired a new position in shares of Bioventus in the 2nd quarter worth approximately $67,000. SG Americas Securities LLC bought a new stake in shares of Bioventus in the 4th quarter worth approximately $80,000. Finally, HB Wealth Management LLC bought a new stake in shares of Bioventus in the 3rd quarter worth approximately $72,000. 62.94% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BVS shares. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Barrington Research increased their price target on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Craig Hallum raised their price target on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.25.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.